Change in concentration of ammonia and other biochemical indicators in patients with new coronaviral infection

The article demonstrates the results of a study to study the comparative assessment of the concentration of ammonia in the peripheral blood of patients with a viral infection of COVID-19 against the background of previously existing hepatic pathology and without it. There was a correlation between peripheral blood hyperammonemia and an increase in the concentration of markers of acute inflammation. The relationship between a high degree of hyperammonemia and a severe course / death as a result of the development of a new coronavirus infection in the studied patients was traced. The role of the initial chronic hepatic pathology (including non-alcoholic fatty liver disease) as a factor in the unfavorable course of the new coronavirus infection is highlighted.

1. Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”. Version 10 (08.02.2021) (In Russ.)

2. Xu L., Liu J., Lu M., et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40(5):998–1004. doi: 10.1111/liv.14435

3. Young B.E., Ong S. W. X., Kalimuddin S., et al. Epidemio logic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020; 323(15): 1488–94. doi: 10.1001/jama.2020.3204. Erratum in: JAMA. 2020 Apr 21;323(15):1510. PMID: 32125362; PMCID: PMC7054855.

4. Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. doi:10.1001/jama.2020.6775

5. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal- Oral Transmission. Gastroenterology. 2020 May;158(6):1518–1519. doi: 10.1053/j.gastro.2020.02.054. Epub 2020 Mar 3. PMID: 32142785; PMCID: PMC7130192.

6. F Del Zompo 1, M De Siena, G Ianiro, A Gasbarrini, M Pompili, F R Ponziani Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis. Eur Rev Med Pharmacol Sci. 2020 Dec;24(24):13072–13088. doi: 10.26355/eurrev_202012_24215

7. Boggs W. Liver Injury Common With COVID-19. March 13, 2020 Available at: https://www.medscape.com/viewarticle/926628 ; Sun J., Aghemo A., Forner A., Valenti L. COVID-19 and liver disease. doi: 10.111

8. Jia B., Yu Z. J., Duan Z. F., et al. Hyperammonaemia induces hepatic injury with alteration of gene expression profi les. Liver Int. 2014 May;34(5):748–58. doi: 10.1111/liv.12365. Epub 2013 Nov 20. PMID: 24134218.

9. Ageyeva Ye.A., Alekseyenko S. А. Use of Oral L-Ornithine- L-Aspartate (LOLA) in the Treatment of Hyperammonemia in Patients with Chronic Liver Disease in the Pre- Cirrhotic Stage. Effective Pharmacotherapy. 2017. Issue 16. Gastroenterology, pp. 6–8. (in Russ.)

10. Bogomolov P.O., Bueverov A. O., Uvarova O. V., Matsievich M. V. Hyperammonemia in patients with pre-cirrhotic liver disease: is it possible? Clinical perspectives of gastroenterology, hepatology. 2013. No. 5, pp. 3–8. (in Russ.)

11. Lazebnik L. B., Golovanova E. V., Alekseenko S. A., et al. Russian Consensus “Hyperammonemia in Adults”. Experimental and Clinical Gastroenterology. 2019;(12):4– 23. (In Russ.) doi: 10.31146/1682–8658-ecg-172–12–4–23

12. Guan W. J. Clinical characteristics of coronavirus disease 2019 in China / W. J. Guan, Z. Y. Ni, Hu Y., et al. New England journal of medicine. 2020; 382: 18: 1708–1720.

13. Han H. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. H. Han, L. Yang, R. Liu., et al. Clinical Chemistry and Laboratory Medicine (CCLM). 2020; 1–5.ahead-of-print (Accessed: 15.11.2020).

14. Murkamilov I.Т. the relationship between markers of inflammation and the morphofunctional state of erythrocytes and platelets in the new coronavirus disease 2019 (covid-19). Journal” Herald of KRSU”, 2021 year, Tom 21, no 1, p. 43–52. (In Russ.)

15. Targher G., Mantovani A., Byrne C. D. et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction- associated fatty liver disease and increased fibrosis scores. Gut. 2020 Aug;69(8):1545–1547. doi: 10.1136/gutjnl-2020–321611. Epub 2020 May 15. PMID: 32414813.

16. Prins G.H., Olinga P. Potential implications of COVID-19 in non-alcoholic fatty liver disease. Liver Int. 2020 Oct;40(10):2568. doi: 10.1111/liv.14484. Epub 2020 May 25. PMID: 32306495; PMCID: PMC7264616.